Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Esmaeli, B.
Right arrow Articles by Arbuckle, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esmaeli, B.
Right arrow Articles by Arbuckle, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:218-221, 2002
© 2002 European Society for Medical Oncology

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect

B. Esmaeli1,+, G. Hortobagyi2, F. Esteva2, V. Valero2, M. A. Ahmadi1, D. Booser2, N. Ibrahim2, E. Delpassand3 and R. Arbuckle4

1Ophthalmology Section, Department of Plastic Surgery; 2Department of Breast Medical Oncology; 3Department of Nuclear Medicine; and 4Department of Pharmacoeconomics, UT M.D. Anderson Cancer Center, Houston, TX, USA

Received 16 August 2001; accepted 27 August 2001.

Background

The purpose of this study was to describe canalicular stenosis as a mechanism for epiphora (excessive tearing) secondary to weekly docetaxel.

Patients and methods

Fourteen patients with metastatic breast cancer who developed epiphora during weekly docetaxel therapy underwent an ophthalmologic examination, and probing and irrigation of the nasolacrimal ducts. The total duration of docetaxel therapy, the duration of treatment at the time of onset of epiphora, the number of infusions, the cumulative dose of docetaxel and the severity of canalicular stenosis were recorded.

Results

All 14 patients had anatomic narrowing of the canaliculi as the underlying mechanism for epiphora. Bicanalicular silicone intubation or dacryocystorhinostomy (DCR) was recommended for all 14 patients. Eleven patients underwent surgery and experienced resolution of their symptoms. The three patients who declined surgery continue to have epiphora at the time of this report.

Conclusions

Canalicular stenosis is an underlying mechanism for epiphora in patients receiving weekly docetaxel. Bicanalicular silicone intubation should be considered early in the course of weekly docetaxel therapy to prevent complete closure of the canaliculi. Once complete or near complete stenosis of the canaliculi occurs, DCR with a permanent pyrex glass tube placement may become necessary to overcome the blockage of tear outflow.

Key words: bicanalicular silicone intubation, breast neoplasms, canalicular stenosis, docetaxel, epiphora, lacrimal apparatus diseases


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Leyssens, H. Wildiers, J. P. Lobelle, A. Gillis, R. Paridaens, and I. Mombaerts
A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis
Ann. Onc., February 1, 2010; 21(2): 419 - 423.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Esmaeli, S. Amin, V. Valero, R. Adinin, R. Arbuckle, R. Banay, K.-A. Do, and E. Rivera
Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel
J. Clin. Oncol., August 1, 2006; 24(22): 3619 - 3622.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. D. Hainsworth
Practical Aspects of Weekly Docetaxel Administration Schedules
Oncologist, September 1, 2004; 9(5): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
B. Esmaeli, M. A. Ahmadi, E. Rivera, V. Valero, T. Hutto, D. M. Jackson, and R. A. Newman
Docetaxel Secretion in Tears: Association With Lacrimal Drainage Obstruction
Arch Ophthalmol, September 1, 2002; 120(9): 1180 - 1182.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.